Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Acosta

Showing results (281-290 of 338) with videos related to

Pageof 34
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|September 14, 2020
Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097Diana F Clarke, Jos Lommerse, Edward P Acosta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2006
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group StudyHeather J Ribaudo, David W Haas, Camlin Tierney, et al.
The Journal of Infectious Diseases|February 14, 2008
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjectsDaniel R Kuritzkes, Christina M Lalama, Heather J Ribaudo, et al.
Pharmacogenetics and Genomics|May 31, 2018
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse eventsDavid W Haas, Yuki Bradford, Anurag Verma, et al.
Pharmacogenetics and Genomics|October 20, 2012
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variantsEmily R Holzinger, Benjamin Grady, Marylyn D Ritchie, et al.
Antiviral Therapy|August 3, 2007
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115Sharon A Riddler, Hongyu Jiang, Allan Tenorio, et al.
Plos Neglected Tropical Diseases|June 13, 2019
Maternal, placental and cord blood cytokines and the risk of adverse birth outcomes among pregnant women infected with Schistosoma japonicum in the PhilippinesAjibola I Abioye, Emily A McDonald, Sangshin Park, et al.
Alzheimer Disease and Associated Disorders|May 29, 2026
Valacyclovir Treatment in Mild Cognitive Impairment: The VALMCI Randomized Clinical TrialDavangere P Devanand, Edward D Huey, Min Qian, et al.
AIDS (London, England)|November 6, 2019
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosisTammy Meyers, Pearl Samson, Edward P Acosta, et al.
AIDS (London, England)|September 13, 2000
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370D R Kuritzkes, R L Bassett, V A Johnson, et al.
Pageof 34

Showing results (281-290 of 338) with videos related to

Sort By:
Pageof 34
Journal of Acquired Immune Deficiency Syndromes (1999)|September 14, 2020
Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097Diana F Clarke, Jos Lommerse, Edward P Acosta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2006
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group StudyHeather J Ribaudo, David W Haas, Camlin Tierney, et al.
The Journal of Infectious Diseases|February 14, 2008
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjectsDaniel R Kuritzkes, Christina M Lalama, Heather J Ribaudo, et al.
Pharmacogenetics and Genomics|May 31, 2018
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse eventsDavid W Haas, Yuki Bradford, Anurag Verma, et al.
Pharmacogenetics and Genomics|October 20, 2012
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variantsEmily R Holzinger, Benjamin Grady, Marylyn D Ritchie, et al.
Antiviral Therapy|August 3, 2007
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115Sharon A Riddler, Hongyu Jiang, Allan Tenorio, et al.
Plos Neglected Tropical Diseases|June 13, 2019
Maternal, placental and cord blood cytokines and the risk of adverse birth outcomes among pregnant women infected with Schistosoma japonicum in the PhilippinesAjibola I Abioye, Emily A McDonald, Sangshin Park, et al.
Alzheimer Disease and Associated Disorders|May 29, 2026
Valacyclovir Treatment in Mild Cognitive Impairment: The VALMCI Randomized Clinical TrialDavangere P Devanand, Edward D Huey, Min Qian, et al.
AIDS (London, England)|November 6, 2019
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosisTammy Meyers, Pearl Samson, Edward P Acosta, et al.
AIDS (London, England)|September 13, 2000
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370D R Kuritzkes, R L Bassett, V A Johnson, et al.
Pageof 34